Emergent BioSolutions(US:EBS) Globenewswire·2026-02-26 21:05Core Insights - Emergent BioSolutions Inc. reported significant progress in its multi-year turnaround strategy, achieving improved operating margins and strong adjusted EBITDA of $205 million for the year ended December 31, 2025 [2][4]. Financial Highlights - Q4 2025 total revenues were $148.7 million, a decrease of 24% from Q4 2024's $194.7 million [3][5]. - Q4 2025 net loss was $54.6 million, compared to a net loss of $31.3 million in Q4 2024, representing a 74% increase in losses [3][5]. - Full year 2025 total revenues were $742.9 million, down 29% from $1,043.6 million in 2024 [4][5]. - Full year 2025 net income was $52.6 million, a turnaround from a net loss of $190.6 million in 2024, marking a 128% improvement [4][5]. - Adjusted EBITDA for the full year 2025 was $205 million, up 12% from $183.1 million in 2024 [4][5]. Segment Performance - Revenues from Commercial Products in Q4 2025 were $38.4 million, down 41% from $65.1 million in Q4 2024, primarily due to lower sales of OTC NARCAN [8][23]. - MCM Products revenues in Q4 2025 were $99.2 million, a decrease of 15% from $116.8 million in Q4 2024 [26]. - Full year 2025 revenues from MCM Products were $456.7 million, down 10% from $509.8 million in 2024 [33]. Cost and Margin Analysis - Q4 2025 cost of product and services sales decreased by 28% to $84.9 million compared to Q4 2024 [16][17]. - Full year 2025 gross margin percentage for MCM Products increased to 58%, up 6 percentage points from the previous year [36]. - Full year 2025 adjusted gross margin percentage was 54%, reflecting an expansion of 900 basis points compared to the prior year [5]. Future Outlook - The company forecasts total revenues for 2026 to be between $720 million and $760 million, with a projected net loss of $30 million to $10 million [38]. - Adjusted net income for 2026 is expected to be between $25 million and $45 million, with adjusted EBITDA forecasted at $135 million to $155 million [38].